Inmune Bio, Inc.   Report issue

For profit Phase 2
Founded: La Jolla CA United States (2015)

Organization Overview

First Clinical Trial
2019
NCT03943264
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

INmune Bio | Inmune Bio, Inc.